Tamoxifen in breast cancer survivors with COVID 19: stop or go?

dc.contributor.author	Karaçin, Cengiz
dc.contributor.author	Karaçin, Pınar
dc.contributor.author	Ergün, Yakup
dc.date.accessioned	2022-07-28T07:43:08Z
dc.date.available	2022-07-28T07:43:08Z
dc.date.issued	2021	en_US
dc.identifier.citation	Karacin, C., Karacin, P., & Ergun, Y. (2021). Tamoxifen in breast cancer survivors with COVID 19: stop or go?. Medical oncology (Northwood, London, England), 38(4), 42. https://doi.org/10.1007/s12032-021-01492-z	en_US
dc.identifier.issn	1357-0560
dc.identifier.issn	1559-131X
dc.identifier.uri	https://doi.org/10.1007/s12032-021-01492-z
dc.identifier.uri	https://hdl.handle.net/11436/6279
dc.description.abstract	The COVID 19 pandemic threatens human health in many ways. Although vaccines that have completed phase 3 trials are being used today, it is estimated that the risk of infection will continue for a while	en_US
dc.language.iso	eng	en_US
dc.publisher	Springer	en_US
dc.rights	info:eu-repo/semantics/closedAccess	en_US
dc.title	Tamoxifen in breast cancer survivors with COVID 19: stop or go?	en_US
dc.type	letter	en_US
dc.contributor.department	RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü	en_US
dc.contributor.institutionauthor	Karaçin, Cengiz
dc.contributor.institutionauthor	Karaçin, Pınar
dc.identifier.doi	10.1007/s12032-021-01492-z	en_US
dc.identifier.volume	38	en_US
dc.identifier.issue	4	en_US
dc.identifier.startpage	42	en_US
dc.relation.journal	Medical Oncology	en_US
dc.relation.publicationcategory	Diğer	en_US